热门资讯> 正文
Can-Fite BioPharma推出尽力而为的ADS和担保书
2025-07-24 05:41
- Can-Fite BioPharma (NYSE:CANF) is offering up to 4.9 million ADSs (representing 1.47 billion ordinary shares) and 4.9 million common warrants in a best-efforts offering.
- Each ADS will be sold with one common warrant at an assumed combined price of $1.02/unit.
- Pre-funded warrants are also offered as an alternative for buyers who would exceed 4.99% (or 9.99%) ownership thresholds post-offering.
- Each pre-funded warrant, priced at $1.019, is exercisable immediately and comes with one common warrant.
- The offering also includes up to 343,138 placement agent qarrants, representing 102.9 million ordinary shares.
- In total, up to 10.1 million ADSs (3.04 billion ordinary shares) may be issued upon full exercise of all warrants.
- All Common Warrants will have a 5-year term and become exercisable upon issuance.
- Source: SEC filing
More on Can-Fite Biopharma
- Seeking Alpha’s Quant Rating on Can-Fite Biopharma
- Historical earnings data for Can-Fite Biopharma
- Financial information for Can-Fite Biopharma
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
